Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.

C Sloane Furniss^1,2, Matthew B Yurgelun^1,2,3, Chinedu Ukaegbu¹, Pamela E Constantinou⁴, Catherine C Lafferty¹, Eliana R Talcove-Berko¹, Alison N Schwartz¹, Jill E Stopfer¹, Meghan Underhill-Blazey¹, Barbara Kenner⁵, Scott H Nelson⁶, Sydney Okumura⁷, Sherman Law⁷, Alicia Y Zhou⁷, Tara B Coffin⁸, Nicolette J Rodriguez^1,2,3, Hajime Uno^1,2, Allyson J Ocean⁹, Florencia McAllister⁴, Andrew M Lowy¹⁰, Scott M Lippman¹⁰, Alison P Klein¹¹, Lisa Madlensky¹⁰, Gloria M Petersen¹², Judy E Garber^1,2,3, Michael G Goggins¹¹, Anirban Maitra⁴, Sapna Syngal^13,2,3

¹Dana-Farber Cancer Institute, Boston, Massachusetts.

²Harvard Medical School, Boston, Massachusetts.

³Brigham and Women's Hospital, Boston, Massachusetts.

⁴Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas, MD Anderson Cancer Center, Houston, Texas.

⁵Kenner Family Research Fund, New York, New York.

⁶Pancreatic Cancer Action Network Volunteer, Patient Advocate, and Pancreatic Cancer Survivor, St. Anthony, Minnesota.

⁷Color Genomics, Burlingame, California.

⁸University of Washington, Seattle, Washington.

⁹Weill Cornell Medical Center, New York, New York.

¹⁰Moores Cancer Center, UC San Diego, San Diego, California.

¹¹Johns Hopkins University, Sol Goldman Pancreatic Cancer Research Center, Baltimore, Maryland.

¹²Mayo Clinic, Rochester, Minnesota.

¹³Dana-Farber Cancer Institute, Boston, Massachusetts. sapna_syngal@dfci.harvard.edu.

PubMed PMC DOI PDF

Abstract

Up to 10% of patients with pancreatic ductal adenocarcinoma (PDAC) carry underlying germline pathogenic variants in cancer susceptibility genes. The GENetic Education Risk Assessment and TEsting (GENERATE) study aimed to evaluate novel methods of genetic education and testing in relatives of patients with PDAC. Eligible individuals had a family history of PDAC and a relative with a germline pathog…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Color Genomics
affiliation

NIH Funding

Grant #11144373
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study
JOHNS HOPKINS UNIVERSITY
$706,934 (FY2025)

Other Funding

NCI NIH HHS(R01 CA176828)
United States
NCI NIH HHS(P50 CA062924)
United States
NCI NIH HHS(U01 CA210170)
United States
NCI NIH HHS(P50 CA102701)
United States
NIDDK NIH HHS(T32 DK007533)
United States

MeSH Terms

Adolescent0Adult0Aged0Aged, 80 and over0BRCA1 Protein0BRCA2 Protein0Carcinoma, Pancreatic Ductal0Female0Genetic Predisposition to Disease*Genetic Testing0Germ-Line Mutation*Humans0Male0Middle Aged0Models, Genetic0Pancreatic Neoplasms0Patient Participation0Risk Assessment0Risk Factors0Surveys and Questionnaires0Telemedicine0Young Adult0

Article Info

PMID: 34625409
PMCID: PMC8563400
DOI: 10.1158/1940-6207.CAPR-20-0642
Received: December 21, 2020
Accepted: July 9, 2021

How to Cite

Furniss CS et al. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prev Res (Phila)2021;14(11):1021-1032. doi:10.1158/1940-6207.CAPR-20-0642

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.